{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-022631","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.786818+00:00","generated_at":"2026-05-16T19:39:28.059055+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"GT Biopharma reports Q3 2025 net loss of $3.1M; cash $2.6M funds into Q1 2026","bullets":["Net loss of $3.1M for Q3 2025 improved from $3.4M in Q3 2024.","Cash and equivalents $2.6M expected to fund operations into Q1 2026.","R&D expenses fell to $0.6M from $1.3M due to lower production and material costs.","Phase 1 GTB-3650 trial now in Cohort 4 at 10 µg/kg/day; next update Q1 2026.","GTB-5550 IND submission for B7H3 tumors expected late Dec 2025 or Jan 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-022631","json":"https://secwatch.observer/filing/0001493152-25-022631.json","markdown":"https://secwatch.observer/filing/0001493152-25-022631.md","text":"https://secwatch.observer/filing/0001493152-25-022631.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315225022631/0001493152-25-022631-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315225022631/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:39:28.059055+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}